Standard Versus Cyclic Teriparatide and Denosumab Treatment for Osteoporosis: A Randomized Trial

What Was Tested

Researchers studied Teriparatide in this randomized controlled trial publication.

Because denosumab is a potent antiresorptive agent with a rapid off-effect, the researchers hypothesized that it might be the optimal agent to help maximize bone gains with cyclic teriparatide.

BMD (dual-energy X-ray absorptiometry [DXA]) measurements of lumbar spine (LS), total hip (TH), femoral neck (FN), and 1/3 radius (RAD) were performed every 6 months and total body bone mineral (TBBM) at 18 and 36 months.

Who Took Part

The study group was 70 women.

The age groups tagged for this paper are older adults.

In this 3-year protocol, 70 postmenopausal women with osteoporosis were randomized to 18 months of teriparatide followed by 18 months of denosumab (standard) or three separate 12-month cycles of 6 months of teriparatide followed by 6 months of denosumab (cyclic).

How the Study Was Run

In design terms this was a randomized study.

Because people in this Teriparatide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

What Was Measured

BMD (dual-energy X-ray absorptiometry [DXA]) measurements of lumbar spine (LS), total hip (TH), femoral neck (FN), and 1/3 radius (RAD) were performed every 6 months and total body bone mineral (TBBM) at 18 and 36 months.

The subject headings attached to it are Bone Density, Bone Density Conservation Agents, Denosumab, Osteoporosis, Osteoporosis, Postmenopausal, Reference Standards and Teriparatide.

Author keywords: ANABOLIC, ANTIRESORPTIVE and SEQUENTIAL.

What This Means in Plain Language

The paper is a randomized study of Teriparatide in 70 women.

The publication is from 2020 (Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research), a journal based in England.

More context: the Teriparatide compound page, all human trials.